Bermuda-based insurance holding company. Opportunistic buy-operate-sell model. AGI Score: 4/10. P/TB 1.07. Buybacks -17%. | Analysis date: 2026-03-13
White Mountains is a Berkshire-lite: a holding company that buys insurance/financial services businesses at attractive prices, operates them, and sells when valuations are rich. Trading near book value (P/B 0.99) with consistent buybacks. Only ~2,500 shares outstanding (ultra-low float). The question: is this a mini-Berkshire that compounds at 10%+ with low risk, or is it an insurance company disguised as a holding company?
White Mountains is a Bermuda-based holding company that makes opportunistic acquisitions in insurance and financial services. Key segments:
Business model: buy-operate-sell when valuations are attractive. Management explicitly targets book value growth per share as the primary metric. 1,648 employees.
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $521M | $945M | $1.2B | $2.2B | $2.2B | $3.7B |
| Net Income | $663M | -$322M | $712M | $581M | $284M | $1.2B |
| Operating Cash Flow | -$61M | $39M | $365M | $404M | $587M | $550M |
| Total Assets | $4.8B | $7.0B | $7.4B | $8.4B | $9.9B | $12.3B |
| Stockholders' Equity | $3.8B | $3.7B | $3.9B | $4.6B | $5.1B | $6.1B |
| Goodwill | $526M | $646M | $176M | $169M | $439M | $614M |
| Intangible Assets | $9M | $176M | $176M | $202M | $281M | $406M |
| Long-Term Debt | $376M | $693M | $575M | $579M | $576M | $852M |
| Shares Outstanding | 3,058 | 2,960 | 2,711 | 2,669 | 2,581 | 2,467 |
| Year | Equity | Shares | BV/Share | Change |
|---|---|---|---|---|
| 2020 | $3.8B | 3,058 | $1,243 | — |
| 2021 | $3.7B | 2,960 | $1,250 | +0.6% |
| 2022 | $3.9B | 2,711 | $1,439 | +15.1% |
| 2023 | $4.6B | 2,669 | $1,724 | +19.8% |
| 2024 | $5.1B | 2,581 | $1,976 | +14.6% |
| 2025 | $6.1B | 2,467 | $2,473 | +25.2% |
Book value per share grew from $1,243 to $2,473 in 5 years = 99% total = ~15% CAGR. This is exceptional. Stock price ($2,195) trails book value ($2,473), meaning you're buying at a discount to growing book. The combination of equity growth + buybacks is compounding at a high rate.
Insurance underwriting, claims processing, and actuarial modeling are areas where AGI provides significant efficiency gains. White Mountains could benefit from better risk selection and lower operating costs. However, the company is a holding company — value depends on portfolio performance, not direct operations.
Current market cap: $5.4B. For 10x = $54B. WTM would need to become a $54B insurance conglomerate. Possible but would require decades of compounding at 15%+, plus acquisitions.
More realistic path: If BV/share continues growing at 15% CAGR (its 5-year rate) and eventually trades at 1.5x book, in 10 years BV/share = $2,473 × (1.15)^10 = $10,005. At 1.5x = $15,008/share = 6.8x from current. Close to 10x but requires sustained excellence.
10x entry price: ~$220/share. At that price the stock would be at 0.09x book — would require a catastrophic insurance loss event.
Verdict: WTM is a 5-7x candidate over a decade, not a 10x from current price. But it's one of the highest-quality compounders in this batch. The risk-adjusted return profile is excellent: low beta (0.35), consistent book value growth, minimal debt, and smart capital allocation.
| Method | Value/Share | vs Current ($2,195) | Assumptions |
|---|---|---|---|
| Tangible Book Value | $2,060 | -6% | ($6.1B - $614M - $406M) / 2,467 shares |
| Book Value (reported) | $2,473 | +13% | $6.1B / 2,467 shares |
| Trough BV (insurance loss scenario) | $1,600 | -27% | Assumes 30% hit to equity from catastrophic losses |
| Liquidation (conservative) | $1,800 | -18% | 80% of book value after wind-down costs |
Floor estimate: ~$1,600-1,800/share. Confidence: High. Insurance balance sheets are well-regulated, and WTM has conservative reserves. The holding company structure provides transparency. Downside is bounded by tangible assets and regulated insurance reserves.
WTM is a mini-Berkshire compounding book value at ~15% annually with smart buybacks and a disciplined buy-operate-sell model. Trading at 0.99x book, which is roughly fair value. The 5-year track record (99% BV/share growth) is impressive. Low beta (0.35) means this stock barely moves with the market.
Not a 10x candidate from current price, but an excellent 5-7x over a decade if the compounding continues. The risk-adjusted profile is among the best in this batch: low downside (floor ~$1,600), steady compounding, conservative management, minimal AGI disruption risk.
WATCHLIST — buy on dips. Ideal entry would be at or below tangible book (~$2,060). At book value or below, this is one of the higher-conviction long-term compounders available.
Data sources: SEC EDGAR XBRL (CIK 776867), yfinance, 10-K filing. Analysis date: 2026-03-13.